Daiwa Pharmaceutical Corporation   Report issue

For profit Phase 2
Founded: Tokyo Japan (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2012
NCT02690103
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Daiwa Health Development | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan

Active Ingredients

Drugs in Phase 2 Trials (3)

hemicellulose (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Other Trials (1)

oryza sativa (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4